SCHEMBL26529985

SCHEMBL26529985

CCC(=O)N1CCC(Cc2nc(-c3cccnc3)no2)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 1/20 0.49
RAB9A P51151 5/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
KDM4E B2RXH2 1/20 0.47
HTT P42858 2/20 0.47
ALDH1A1 P00352 1/20 0.46
KMT2A Q03164 3/20 0.46
NPC1 O15118 3/20 0.46
EPHX2 P34913 2/20 0.46
TP53 P04637 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HRH3 Q9Y5N1 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
TSHR P16473 2/20 0.46
RECQL P46063 1/20 0.46
LDHA P00338 1/20 0.46
MAPK1 P28482 3/20 0.45
MEN1 O00255 1/20 0.45
GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26529982 0.92 PPARA (0.50) PPARARAB9AL3MBTL1KDM4EHTT
SCHEMBL26529989 0.91 RAB9A (0.49) PPARARAB9AL3MBTL1KDM4EHTT
SCHEMBL26530005 0.87 ALDH1A1 (0.47) PPARARAB9AL3MBTL1KDM4EHTT
SCHEMBL26530003 0.85 CYP1A2 (0.56) RAB9AL3MBTL1HTTALDH1A1NPC1
SCHEMBL26530001 0.84 HTT (0.54) PPARARAB9AL3MBTL1HTTALDH1A1
SCHEMBL26530008 0.84 LMNA (0.50) RAB9AL3MBTL1KDM4EHTTALDH1A1
SCHEMBL26530018 0.83 HTT (0.57) PPARARAB9AKDM4EHTTALDH1A1
SCHEMBL26529992 0.82 ALDH1A1 (0.51) RAB9AKDM4EHTTALDH1A1KMT2A
SCHEMBL26529999 0.82 TSHR (0.49) PPARARAB9AL3MBTL1KDM4EHTT
SCHEMBL26529996 0.81 HTT (0.47) PPARAL3MBTL1KDM4EHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322715-A1 BROAD SPECTRUM ANTI-CANCER COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-10-12 US disclosed
US-20230322715-A1 BROAD SPECTRUM ANTI-CANCER COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322715-A1 BROAD SPECTRUM ANTI-CANCER COMPOUNDS YTHDF1, YTHDF3, YTHDF2 PPARA 1786/4885RAB9A 2759/4885L3MBTL1 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.